Development and structure–activity relationships of tanshinones as selective 11β-hydroxysteroid dehydrogenase 1 inhibitors
Open Access
- 22 September 2022
- journal article
- research article
- Published by Springer Nature in Natural Products and Bioprospecting
- Vol. 12 (1) , 1-13
Abstract
11β-Hydroxysteroid dehydrogenase 1 (11β-HSD1) represents a promising drug target for metabolic syndrome, including obesity and type 2 diabetes. Our initial screen of a collection of natural products from Danshen led to the identification of tanshinones as the potent and selective 11β-HSD1 inhibitors. To improve the druggability and explore the structure–activity relationships (SARs), more than 40 derivatives have been designed and synthesized using tanshinone IIA and cryptotanshinone as the starting materials. More than 10 derivatives exhibited potent in vitro 11β-HSD1 inhibitory activity and good selectivity over 11β-HSD2 across human and mouse species. Based on the biological results, SARs were further discussed, which was also partially rationalized by a molecular docking model of 1 bound to the 11β-HSD1. Remarkably, compounds 1, 17 and 30 significantly inhibited 11β-HSD1 in 3T3-L1 adipocyte and in livers of ob/ob mice, which merits further investigations as anti-diabetic agents. This study not only provides a series of novel selective 11β-HSD1 inhibitors with promising therapeutic potentials in metabolic syndromes, but also expands the boundaries of the chemical and biological spaces of tanshinones. Graphic AbstractKeywords
Funding Information
- National Natural Science Foundation of China (U1502223)
- Hunan Provincial Key Research and Development Project (2021WK2005)
- Natural Science Foundation of Hunan Province (2021JJ30894)
- the open fund of State Key Laboratory of Phytochemistry and Plant Resource in West China (P2020-KF03)
This publication has 47 references indexed in Scilit:
- 11β-HSD1 Inhibitors for the Treatment of Type 2 Diabetes and Cardiovascular DiseaseDrugs, 2013
- Regio‐ and Stereoselective [4+3] Cycloaddition Towards Fused 5,7,6‐Tricyclic SkeletonsChemistry – An Asian Journal, 2013
- Tanshinone derivatives: a patent review (January 2006 – September 2012)Expert Opinion on Therapeutic Patents, 2012
- Inhibition of 11ß-hydroxysteroid dehydrogenase type 1 as a promising therapeutic targetDrug Discovery Today, 2007
- Metabolic syndrome, or What you will: definitions and epidemiologyDiabetes & Vascular Disease Research, 2007
- Mechanisms of Disease: selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndromeNature Clinical Practice Endocrinology & Metabolism, 2005
- High-Throughput Screening of 11β-Hydroxysteroid Dehydrogenase Type 1 in Scintillation Proximity Assay FormatASSAY and Drug Development Technologies, 2005
- Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking AccuracyJournal of Medicinal Chemistry, 2004
- Synthesis of 3-Deaza-β-hydroxyhistidine Derivatives and Their Use for the Preparation of Substituted Pyrrolo[2,3-c]pyridine-5-carboxylates via the Pictet−Spengler ReactionThe Journal of Organic Chemistry, 1998
- Palladium-Catalyzed Cross-Coupling Reactions of Organoboron CompoundsChemical Reviews, 1995